Characterization of the inflammatory proteome of synovial fluid from patients with psoriatic arthritis: Potential treatment targets.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 29 12 2022
accepted: 10 03 2023
medline: 11 4 2023
entrez: 10 4 2023
pubmed: 11 4 2023
Statut: epublish

Résumé

1) To characterize the inflammatory proteome of synovial fluid (SF) from patients with Psoriatic Arthritis (PsA) using a high-quality throughput proteomic platform, and 2) to evaluate its potential to stratify patients according to clinical features. Inflammatory proteome profile of SF from thirteen PsA patients with active knee arthritis were analyzed using proximity extension assay (PEA) technology (Olink Target 96 Inflammation panel). Four patients with OA were included as control group. Seventy-nine inflammation-related proteins were detected in SF from PsA patients (SF-PsA). Unsupervised analyzes of the molecular proteome profile in SF-PsA identified two specific phenotypes characterized by higher or lower levels of inflammation-related proteins. Clinically, SF-PsA with higher levels of inflammatory proteins also showed increased systemic inflammation and altered glucose and lipid metabolisms. Besides, SF from PsA patients showed 39 out of 79 proteins significantly altered compared to SF-OA specifically related to cell migration and inflammatory response. Among these, molecules such as TNFα, IL-17A, IL-6, IL-10, IL-8, ENRAGE, CCL20, TNFSF-14, OSM, IFNγ, MCP-3, CXCL-11, MCP4, CASP-8, CXCL-6, CD-6, ADA, CXCL-10, TNFβ and IL-7 showed the most significantly change. This is the first study that characterizes the inflammatory landscape of synovial fluid of PsA patients by analyzing a panel of 92 inflammatory proteins using PEA technology. Novel SF proteins have been described as potential pathogenic molecules involved in the pathogenesis of PsA. Despite the flare, inflammatory proteome could distinguish two different phenotypes related to systemic inflammation and lipid and glucose alterations.

Identifiants

pubmed: 37033920
doi: 10.3389/fimmu.2023.1133435
pmc: PMC10073963
doi:

Substances chimiques

Proteome 0
Lipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1133435

Informations de copyright

Copyright © 2023 Barbarroja, López-Montilla, Cuesta-López, Pérez-Sánchez, Ruiz-Ponce, López-Medina, Ladehesa-Pineda, López-Pedrera, Escudero-Contreras, Collantes-Estévez and Arias-de la Rosa.

Déclaration de conflit d'intérêts

Authors NB, CP-S and CL-M were co-founders of the company Cobiomic Bioscience S.L. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Rheumatol Int. 2013 Jan;33(1):265-6
pubmed: 22083617
Osteoarthr Cartil Open. 2022 Jul 07;4(3):100293
pubmed: 36474941
J Rheumatol. 1997 Mar;24(3):518-23
pubmed: 9058659
Nucleic Acids Res. 2011 Aug;39(15):e102
pubmed: 21646338
J Intern Med. 2022 May;291(5):676-693
pubmed: 35233860
Arthritis Rheum. 2011 Apr;63(4):914-22
pubmed: 21225692
Curr Rheumatol Rev. 2017;13(3):170-179
pubmed: 28460627
Clin Proteomics. 2014 Jul 01;11(1):27
pubmed: 25097465
Rheumatol Ther. 2019 Sep;6(3):305-315
pubmed: 31102105
Lancet. 2018 Jun 2;391(10136):2273-2284
pubmed: 29893226
Arthritis Rheum. 2006 Aug;54(8):2665-73
pubmed: 16871531
Rheumatology (Oxford). 2021 Feb 1;60(2):751-761
pubmed: 32793974

Auteurs

Nuria Barbarroja (N)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.
Cobiomic Bioscience S.L, Cordoba, Spain.

Maria Dolores López-Montilla (MD)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Laura Cuesta-López (L)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Carlos Pérez-Sánchez (C)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.
Cobiomic Bioscience S.L, Cordoba, Spain.

Miriam Ruiz-Ponce (M)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Clementina López-Medina (C)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.
Cobiomic Bioscience S.L, Cordoba, Spain.

Maria Lourdes Ladehesa-Pineda (ML)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Chary López-Pedrera (C)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Alejandro Escudero-Contreras (A)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Eduardo Collantes-Estévez (E)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Iván Arias-de la Rosa (I)

Rheumatology Service/Department of Medical and Surgical Sciences, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Córdoba, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH